OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company's pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Stock data | 2023 | Change |
---|---|---|
Price | $0.2756086357372531 | N/A |
Market Cap | $53.09M | N/A |
Shares Outstanding | 192.64M | 2.76% |
Employees | 60.00 | N/A |
Shareholder Equity | 855.17M | -56.81% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -0.05 | N/A |
P/S Ratio | 6.62 | N/A |
P/B Ratio | 0.06 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.0092 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $8.02M | N/A |
Earnings | -$7.91M | N/A |
EPS | -5.81 | N/A |
Earnings Yield | -21.08 | N/A |
Gross Margin | 0.0367 | N/A |
Operating Margin | -0.9749 | N/A |
Net income margin | -0.9857 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $10.68M | N/A |
Cash on Hand | $7.90M | N/A |
Debt to Equity | 0.0054 | 115.57% |
Current Ratio | $2.33 | -45.70% |